Discovery of Highly Selective PARP7 Inhibitors with a Novel Scaffold for Cancer Immunotherapy
- 7 December 2023
- journal article
- research article
- Published by American Chemical Society (ACS) in Journal of Medicinal Chemistry
- Vol. 67 (3) , 1932-1948
Abstract
PARP7 plays a crucial role in cancer immunity. The inhibition of PARP7 has shown potential in boosting the immune response against cancer, making it an attractive target for cancer immunotherapy. Herein, we employed a rigid constraint strategy (reduction in molecular flexibility) to design and synthesize a series of novel indazole-7-carboxamide derivatives based on the structure of RBN-2397. Among these derivatives, (S)-XY-05 was identified as the most promising PARP7 inhibitor (IC50: 4.5 nM). Additionally, (S)-XY-05 showed enhanced selectivity toward PARP7 and improved pharmacokinetic properties (oral bioavailability: 94.60%) compared with RBN-2397 (oral bioavailability: 25.67%). In the CT26 syngeneic mouse model, monotherapy with (S)-XY-05 displayed a strong antitumor effect (TGI: 83%) by activating T-cell-mediated immunity within the tumor microenvironment. Collectively, we confirmed that (S)-XY-05 has profound effects on tumor immunity, which paves the way for future studies of PARP7 inhibitors that could be utilized in cancer immunotherapy.Keywords
Funding Information
- China Pharmaceutical University (CPU2022PZQ03)
- Fundamental Research Funds for the Central Universities (2632023GR21)
- National Natural Science Foundation of China (82304304, 82373744)
This publication has 34 references indexed in Scilit:
- Novel insight into circular RNA HECTD1 in astrocyte activation via autophagy by targeting MIR142-TIPARP: implications for cerebral ischemic strokeAutophagy, 2018
- Structure refinement of membrane proteins via molecular dynamics simulationsProteins: Structure, Function, and Bioinformatics, 2018
- Constitutive aryl hydrocarbon receptor signaling constrains type I interferon–mediated antiviral innate defenseNature Immunology, 2016
- Molecular simulation studies on the binding selectivity of 2-anilino-4-(thiazol-5-yl)-pyrimidines in complexes with CDK2 and CDK7Molecular BioSystems, 2015
- Can structural features of kinase receptors provide clues on selectivity and inhibition? A molecular modeling studyJournal of Molecular Graphics and Modelling, 2015
- Niraparib: A Poly(ADP-ribose) Polymerase (PARP) Inhibitor for the Treatment of Tumors with Defective Homologous Recombination2015
- Induced fit docking, and the use of QM/MM methods in dockingDrug Discovery Today: Technologies, 2013
- A systematic analysis of the PARP protein family identifies new functions critical for cell physiologyNature Communications, 2013
- Induced-fit docking studies of the active and inactive states of protein tyrosine kinasesJournal of Molecular Graphics and Modelling, 2009
- The diverse biological roles of mammalian PARPS, a small but powerful family of poly-ADP-ribose polymerasesFrontiers in Bioscience-Landmark, 2008